Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
HIV Infections: early-phase trial registry
56 of 615 indexed HIV Infections trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7 of 28,707 conditions by registered trial count.
615 US clinical trials · 56 currently recruiting · #7 of 28,707 conditions by registered trial count
HIV Infections: 615 US clinical trials tracked, 56 recruiting.
HIV Infections is the subject of 615 registered US clinical trials on ClinicalTrials.gov, 56 of them currently open to new participants. 92 are in Phase 3-4 (later-stage) and 266 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 195 of these trials.
Enrollment posture brief
Registry condition hiv-infections
OPEN 56 | RECR 9% | LATE 92 | EARLY 266 | RANK #7 | SPON 195
Volume-matched condition peers
Nearest open-share peer: Acute Lung Injury (9% recruiting · 11 trials)
HIV Infections lists 56 open slots (9% of 615 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for HIV Infections on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
HIV Infections is recruiting below its size-band peers.
56 of 615 indexed trials (9.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates HIV Infections research.
National Institute of Allergy and Infectious Diseases (NIAID) accounts for 195 of 615 trials (31.7%). 173 distinct sponsors appear on at least one study for this condition label.
-
Typical HIV Infections enrolment sits around 100 participants.
Median target enrolment is 100 among the 543 trials that report a genuine target (sentinel values excluded). 267 of those (49.2%) plan for fewer than 100 participants.
-
HIV Infections research is mostly interventional.
549 interventional and 66 observational studies make up this index (89.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
615 total, page 7 of 13
A Trial of Alternating 2',3'-Dideoxycytidine and Zidovudine in the Treatment of Patients With Advanced HIV Disease
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000719
Safety of and Immune Response to a New HIV Vaccine: HIV CTL MEP
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00076037
An Affect Management Intervention for Juvenile Offenders
Rhode Island Hospital
NCT00748800
Impact of a Telenovela/Soap Opera for HIV Prevention in Latinas
University of North Carolina, Chapel Hill
NCT05929482
Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00013663
Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00006066
The Safety and Effectiveness of Rifabutin, Combined With Clarithromycin or Azithromycin, in HIV-Infected Patients
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001023
Positive Lifestyles Using Safety
Yale University
NCT00836290
Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)
National Institute of Allergy and Infectious Diseases (NIAID)
NCT05099965
Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00005762
Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000627
Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001048
Aripiprazole Treatment for Methamphetamine Dependence Among High-risk Individuals
San Francisco Department of Public Health
NCT00497055
Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults
National Institute of Allergy and Infectious Diseases (NIAID)
NCT02165267
A Phase I Multiple Dose Pharmacokinetic Study of Nevirapine Extended Release (XR) in HIV-1 Infected Children.
Boehringer Ingelheim
NCT00905489
An Investigational Combination Vaccine Given to People Who Are Not Infected With HIV
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00027365
Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants
National Institute of Allergy and Infectious Diseases (NIAID)
NCT02256631
Young Men's Health Project Targeting HIV Risk Reduction and Substance Abuse
Florida State University
NCT03577301
Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection
University of North Carolina, Chapel Hill
NCT00959894
The Safety and Effectiveness of Indinavir Sulfate Plus Efavirenz
Merck Sharp & Dohme
NCT00002387
The Safety and Effectiveness of Lamivudine Plus Stavudine or Zidovudine in HIV-Infected Patients Who Have Taken Zidovudine
Bristol-Myers Squibb
NCT00002371
Subcutaneously Administered Aldesleukin ( Interleukin-2; IL-2 ) Therapy in HIV-Infected Patients
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000821
"The Once A Day Protease Inhibitor Regimens"
The University of Texas Health Science Center, Houston
NCT00242216
Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) Use With Certain Anti-HIV Drugs in HIV-Infected Women
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00016601
Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants
Alexion Pharmaceuticals
NCT00350272
Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00260078
Endothelial Dysfunction as a Risk Factor in HIV Study
National Institutes of Health Clinical Center (CC)
NCT00039663
A Study of an Adherence Plan to Help HIV-Positive Patients Take Their First Anti-HIV Medications Correctly
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001122
First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants
ViiV Healthcare
NCT05393271
Enhancing Sexual Safety: Couples' Communication and HIV Testing Among YMSM
Florida State University
NCT04289116
Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Gilead Sciences
NCT00869557
Safety of and Immune Response to an HIV-1 Vaccine Boost (VRC-HIVADV014-00-VP) in HIV Uninfected Adults Who Participated in HVTN 052
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00091416
Chloroquine for Reducing Immune Activation in HIV- Infected Individuals
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
NCT00819390
A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults
Hoffmann-La Roche
NCT00002239
Metabolic and Psychological Changes Associated With Menopause Among Women With HIV
Massachusetts General Hospital
NCT01142817
A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients
Hoffmann-La Roche
NCT00089492
Adherence Connection for Counseling, Education, and Support (ACCESS) II
NYU Langone Health
NCT04499781
A Study of Efavirenz in Combination With Stavudine and Didanosine
Dupont Merck
NCT00002225
Study Comparing Racivir and Lamivudine in Treatment-Experienced HIV Subjects
Pharmasset
NCT00121979
A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection
Glaxo Wellcome
NCT00002183
Study to Explore Safety And Tolerability of Fosamprenavir With or Without Ritonavir in Combination With TRIZIVIR or COMBIVIR
GlaxoSmithKline
NCT00043888
Kaletra-isentress Treatment Evaluation
Emory University
NCT00700115
An Evaluation of Pentoxifylline in HIV-Positive Persons With Symptomatic HIV Infection and a Karnofsky Score > 40 Percent and < 100 Percent
Community Research Initiative of New England
NCT00002091
Effects of Changing HIV Therapy at Lower Versus Higher Viral Loads
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00036465
Use of a Varicella-Zoster Virus (VZV) Vaccine to Prevent Shingles in HIV-Infected Children Who Have Already Had Chickenpox
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001125
A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000952
A Study of Timunox (Thymopentin) in HIV-Infected Patients Receiving Other Anti-HIV Drugs
Immunobiology Research Institute
NCT00002332
Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection
University of Cincinnati
NCT00885664
Development and Pilot Testing of the Sense2Quit App
Columbia University
NCT05609032
A Study to Investigate the Effect of Food on the Bioavailability of a Capsid Inhibitor (CAI) in Male and Female Healthy Participants
ViiV Healthcare
NCT06368986
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 157 |
| Phase 2 | 109 |
| Phase 3 | 69 |
| Phase 4 | 23 |
Top Sponsors
Named interventions
Most-linked intervention names on HIV Infections records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on HIV Infections trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this HIV Infections page
615 registered trials, 56 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 56 HIV Infections trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute of Allergy and Infectious Diseases (NIAID) sponsors the most HIV Infections trials on record, review their full trial history before evaluating a specific study. See National Institute of Allergy and Infectious Diseases (NIAID)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This HIV Infections condition card totals 615 registered trials; most-linked intervention Zidovudine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.